Surgical Innovations Group PLC Distalmotion's Dexter Robot receives CE Mark
08 January 2021 - 6:00PM
RNS Non-Regulatory
TIDMSUN
Surgical Innovations Group PLC
08 January 2021
Surgical Innovations Group plc
("Surgical Innovations", "SI" or the "Company")
Distalmotion's Dexter Robot receives CE Mark
Surgical Innovations Group plc (AIM: SUN), the designer,
manufacturer and distributor of innovative medical technology for
minimally invasive surgery ("MIS"), announces that Distalmotion SA,
a Swiss-based medical device company providing robotic surgery
systems on a transparent and fair per-procedure cost
("Distalmotion"), has received European CE Mark for its 'Dexter'
surgical robot. Manufactured in Switzerland, Dexter combines the
affordability of laparoscopy with the benefits of robotic surgery
to bring simplicity and versatility in minimally invasive surgical
care.
Elemental Healthcare Limited, a wholly owned SI subsidiary, has
exclusive UK distribution rights for the Dexter Robot.
The European CE mark remains valid in the UK post Brexit.
Adam Power, SI Group Development Director, commented: "The UK
minimally invasive surgical robot market has been dominated by a
single, expensive and very complex robot for nearly two decades.
Dexter is designed to integrate readily into existing laparoscopic
procedures and its simplicity and versatility makes robotics
accessible for a wider range of procedures. The regulatory approval
of the Dexter operating robot now allows the introduction of a
disruptive robotic model to UK healthcare. The ease of use,
affordability and Swiss manufacturing excellence will be
significant factors in the growth opportunity for this new
robot."
Michael Friedrich, CEO, Distalmotion said: "Distalmotion are
looking forward to some early successes in the important UK market
with our partner, Elemental Healthcare. The NHS is especially
appropriate for the Dexter strategic model of selling and we
already have hospitals that are some way into the process of
product acquisition."
For further information please contact:
Surgical Innovations Group plc www sigroupplc com
David Marsh, CEO Tel: 0113 230 7597
Charmaine Day, Co Sec & GFC
N+1 Singer (Nominated Adviser & Tel: 020 7496 3000
Broker)
Aubrey Powell (Corporate Finance)
Rachel Hayes (Corporate Broking)
Walbrook PR (Financial PR & Investor Tel: 020 7933 8780 or si@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303
About Surgical Innovations Group plc
The Group specialises in the design, manufacture, sale and
distribution of innovative, high quality medical products,
primarily for use in minimally invasive surgery. Our product and
business development is guided and supported by a key group of
nationally and internationally renowned surgeons across the
spectrum of minimally invasive surgical activity.
We design and manufacture and source our branded port access
systems, surgical instruments and retraction devices which are sold
directly in the UK home market through our subsidiary, Elemental
Healthcare, and exported widely through a global network of trusted
distribution partners. Many of our products in this field are based
on a "resposable" concept, in which the products are part
re-usable, part disposable, offering a high quality and
environmentally responsible solution at a cost that is competitive
against fully disposable alternatives.
Elemental also has exclusive UK distribution for a select group
of specialist products employed in laparoscopy, bariatric and
metabolic surgery, hernia repair and breast reconstruction.
In addition, we design and develop medical devices for carefully
selected OEM partners, and have also collaborated with a major UK
industrial partner to provide precision engineering solutions to
complex problems outside the medical arena.
We aim for our brands to be recognised and respected by
healthcare professionals in all major geographical markets in which
we operate and provide by development, partnership or acquisition a
broad portfolio of cost effective, procedure specific surgical
instruments and implantable devices that offer reliable solutions
to genuine clinical needs in the operating theatre environment.
The Group currently employs approximately 100 people across two
sites in the UK. Product design, engineering and manufacturing are
carried out at the SI site in Yorkshire. Commercial activities
including marketing, UK distribution and international sales and
marketing are based at Elemental Healthcare in Berkshire.
Further information
Further details of the Group's businesses are available on the
following websites:
www.sigroupplc.com
www.surginno.com
www.elementalhealthcare.co.uk
To receive regular updates by email, please contact
si@walbrookpr.com .
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFLDLDIDIIL
(END) Dow Jones Newswires
January 08, 2021 02:00 ET (07:00 GMT)
Surgical Innovations (LSE:SUN)
Historical Stock Chart
From Apr 2024 to May 2024
Surgical Innovations (LSE:SUN)
Historical Stock Chart
From May 2023 to May 2024